$TLSI News

Lake Street Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $8

TriSalus Life Sciences, Inc. (TLSI) Q1 2026 Earnings Call Transcript

TriSalus Life Sciences (NASDAQ:TLSI) Swings to Surprise Net Profit in Q1, But Revenue Miss Tempers Outlook

TriSalus Life Sciences Q1 2026 Earnings Call: Complete Transcript

TriSalus Life Sciences Lowers FY2026 Sales Guidance from $60.000M-$62.000M to $54.000M-$57.000M vs $59.960M Est

TriSalus Life Sciences Q1 EPS $0.03 Beats $(0.16) Estimate, Sales $8.899M Miss $10.440M Estimate

TriSalus Life Sciences Announces Publication Of Study On Pressure-Enabled Drug Delivery Used In Trans Arterial Chemoembolization And Radioembolization

TriSalus Life Sciences Announced The Initiation Of Patient Enrollment For The PREDICTT Clinical Trial, A Prospective Study Designed To Evaluate Its Novel Pressure-enabled Drug Delivery Approach In Patients With Primary Or Metastatic Liver Tumors

TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting

TriSalus Life Sciences To Participate In the Society Of Interventional Radiology Annual Scientific Meeting, Will Showcase New Clinical Data Highlighting Its Pressure-Enabled Drug Delivery System

TriSalus Life Sciences To Participate In the Society Of Interventional Radiology Annual Scientific Meeting, Will Showcase New Clinical Data Highlighting Its Pressure-Enabled Drug Delivery System

TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer

TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models

TriSalus Life Sciences Publishes Preclinical Research Evaluating Pressure-Enabled Drug Delivery Of Nelitoliod In Liver Tumor Models In 'Frontiers In Oncology'

Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating

Canaccord Genuity Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $7

TriSalus Life Sciences, Inc. Q4 2025 Earnings Call Summary

TriSalus Life Sciences Q4 Earnings Call Highlights

TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...

TriSalus Life Sciences Inc (NASDAQ:TLSI) Reports Q4 Revenue Beat and Narrowed Losses